Lipocalin Levels In Patients Research Articles

ЛИПОКАЛИН СЫВОРОТКИ КРОВИ БОЛЬНЫХ ОСТРЫМ ПАНКРЕАТИТОМ

Abstract. Introduction. Acute pancreatitis is a severe inflammatory disease of the pancreas. In case of severe acute pancreatitis, mortality rate reaches 36-50%. The most challenging issue is the prediction of its severity and clinical outcome due to the limitations of clinical scoring systems and biochemical markers, which are still being studied intensely. Aim: To study serum lipocalin levels in patients with acute pancreatitis of varying severity. Materials and Methods. Our study included 68 patients diagnosed with acute pancreatitis and treated in the inpatient facility of Kazan City Clinical Hospital 7 over the years 2017-2019. Patients were stratified by severity, gender, and age. As a comparison group, 20 healthy volunteers without any gastrointestinal issues were examined. Specimen to be studied were the sera of patients with acute pancreatitis and those of healthy volunteers. Blood was sampled from the patients upon admission to the hospital and before their discharge from it. Lipocalin levels were registered using BioVendor’s Human Lipocalin-2/NGAL ELISA kit. The findings were processed statistically at their normal distribution. Results and Discussion. Our study showed a significant excess of lipocalin levels in patients with acute pancreatitis as compared with healthy volunteers. In healthy volunteers this value varied within 4.91±6.55 ng/ml, while it was 78.19±89.09 ng/ml (p<0.05) in acute pancreatitis patients. Conclusions. Our study of serum lipocalin in patients with acute pancreatitis showed a significant and statistically reliable excess of this indicator as compared to healthy volunteers. The highest lipocalin levels were found in patients with severe acute pancreatitis. Conventional therapy reduced these levels in mild, moderate, and severe cases, although there was no statistically significant difference before and after treatment. Keywords: pancreatic necrosis, lipocalin, prediction.

Neutrophil Gelatinase-Associated Lipocalin Level Can Predict Early Organ Damage in Primary Hypertensive Patients: A Pilot Study.

Early detection and treatment of complicated arterial hypertension will prevent its effect on the target organs. In line with this purpose, we aimed to reveal the prediction capability of neutrophil gelatinase-associated lipocalin to complicated hypertension. In total, 46 patients with hypertension and 21 healthy volunteers were included in the study. Left ventricle morphology and geometry, as systolic and diastolic functions, were analyzed. Global longitudinal strain was measured from recorded apical 3-chamber views. An ophthalmic examination was performed to investigate the presence of retinopathy in individuals with hypertension. In addition, plasma neutrophil gelatinase-associated lipocalin values were evaluated via the method of the enzyme-linked immunosorbent assay. Both neutrophil gelatinase-associated lipocalin levels and global longitudinal strain percentages were statistically significant between the groups with diastolic dysfunction and the groups without diastolic dysfunction. Complicated hypertension was detected in 42 patients. Here, it was found that the neutrophil gelatinase-associated lipocalin level of 144.3 ng/mL predicted complicated hypertension with 0.872 sensitivity and 0.65 specificity values. Analyzing neutrophil gelatinase-associated lipocalin levels in patients with hypertension in routine practice can easily and practically detect complicated hypertension patients earlier.

The Diagnostic and Prognostic Significance of Serum Neutrophil Gelatinase-Associated Lipocalin Levels in Patients with Colorectal Cancer.

Neutrophil gelatinase-associated lipocalin (NGAL) is an inflammatory biomarker that is stored in neutrophil granules. Recent studies revealed that NGAL expression increases in tissue samples of patients with inflammatory gastrointestinal system diseases and cancers. The aim of this study was to evaluate the diagnostic and predictive significance of plasma NGAL levels in various stages of adenoma-carcinoma sequence of colorectal cancer. Materials and Methods: Eighty cases were included in the study and separated into 3 groups. "Cancer Group" consisted of 27 colorectal cancer patients who underwent curative resection, whereas 24 patients with colorectal adenomatous polyps detected by colonoscopy were classified as the "Polyp Group", and 29 patients with normal colonoscopy findings were classified as the "Control Group". The serum NGAL, CEA and CA19-9 levels and histopathology findings were determined. Results: The mean plasma NGAL levels for control group, polyp group and cancer group were found to be 91.5 ng/ml, 139.6ng/ml and 184.3ng/ml, respectively. Plasma NGAL levels were found to be significantly higher in cancer group compared to the control group (p:0.006). Plasma NGAL levels were detected statistically significant and positive correlated with tumor diameter and number of metastatic lymph nodes (p:0.047, r:%38.6 and p:0.026, r:%42.8, respectively) in cancer group. Conclusions: We are of the opinion that pre-operative plasma NGAL level is a potential diagnostic biomarker for colorectal cancer patients. Although more comprehensive studies are needed for definitive judgments, serum NGAL levels may be used as a diagnostic and/or predictive biomarker for lymph node metastasis in patients with colorectal cancer.

Neutrophil Gelatinase-Associated Lipocalin Levels in Patients with Thalassemia and Sickle Cell Disease: Correlation with Renal Injury

Background and Aims: Neutrophil gelatinase-associated lipocalin (NGAL) is a protein belonging to the lipocalin superfamily initially found in activated neutrophils, in accordance with its role as an innate antibacterial factor. However, it subsequently was shown that many other types of cells, including in the kidney tubule, may produce NGAL in response to various injuries. The increase in NGAL production and release from tubular cells after harmful stimuli of various kinds may have self-defensive intent based on the activation of specific iron-dependent pathways, which in all probability also represent the mechanism through which NGAL promotes kidney growth and differentiation. NGAL levels clearly correlate with severity of renal impairment, probably expressing the degree of active damage underlying the chronic condition. For all these reasons, NGAL may become one of the most promising next-generation biomarkers in clinical nephrology and beyond. We aimed to investigate the clinical significance of NGAL levels and its correlation with renal function in patients with hemoglobinopathies.Patients and Methods: 117 adult patients with hemoglobinopathies were included in the study divided in 3 groups. Group A: 30 patients with transfusion-dependent thalassemia major (TM); Group B: 29 patients with Non-Transfusion-Dependent Thalassemia (TI) and Group C: 58 patients with HbS/βthal disease, while 20 apparently healthy individuals served as controls (Group D). In patients and controls along with standard blood and urine chemistry. Measurements of serum Cystatin C and NGAL were performed by means of immunonephelometric and immunoenzymatic techniques, (Siemens Healthcare Diagnostics, Liederbach, Germany and R&D Systems, Minneapolis, MN, USA), respectively. Estimated Glomerular Filtration Rate (eGFR) values were calculated with an unadjusted for body surface Cystatin C based equation: eGFR (mL/min)=77.24(Cys C)-1.2623.Results: The main results of the study showed that: a) NGAL levels were significantly higher in all the groups of patients compared to controls: Group A 95.0±45.0µg/L, Group B 139.1±86.1µg/L, Group C 117.8±37.3µg/L vs Group D 50.3±11.3µg/L (p<0.001), b) Cystatin C levels were significantly higher in patients of Group A 0.94±0.34mg/L and Group C 1.04±0.50mg/L compared to controls 0.75±0.09mg/L (p<0.01), while no significant difference was found between Group B 0.72±0.13mg/L and controls (p>0.300), c) NGAL levels and eGFR values (Group A: 96.9±39.8, Group B: 117.0±26.0, Group C: 86.2±27.8 and group D: 109.6±15.0mL/min, respectively) correlated significantly in patients of Group A and Group C (r=-0.739, p<0.001 and r=-0.735, p<0.001, respectively), while NGAL values are independent from eGFR values in patients of Group B.Conclusions: These findings illustrate the tubular-glomerular activation feedback mirrored by NGAL in patients with transfusion-dependent thalassemia major and HbS/βthal disease, who suffer from renal injuries, indicating that tubular damage precedes GFR reduction. Upregulation of NGAL in patients with non-transfusion-dependent thalassemia independently of renal injuries may reflect the compensatory, protective role of NGAL in response to diverse cellular stresses, including inflammation and oxidative stress. However, recent reports have implicated NGAL upregulation as a mechanism that contributes to anemia in the setting of chronic low grade inflammation. In experimental models, systemic and medullary NGAL has been demonstrated to induce inhibition of erythropoiesis through induction of apoptosis and arrest of differentiation of erythroid progenitor cells. DisclosuresNo relevant conflicts of interest to declare.

Implication of Serum Neutrophil Gelatinase-Associated Lipocalin Levels in Patients Who Underwent First-time Diagnostic Coronary Angiography

Implication of Serum Neutrophil Gelatinase-Associated Lipocalin Levels in Patients Who Underwent First-time Diagnostic Coronary Angiography

Low Serum Lipocalin Levels in Patients With Iron Deficiency Anemia

In the recent literature, there are studies on the relationship between anemia and lipocalin, but there is no study regarding the relationship between lipocalin and iron deficiency anemia (IDA) up to date. In this study, we aimed to observe lipocalin levels at admission, and after iron therapy in children with IDA. We also compared our findings to those in healthy children. Sixty-one children admitted in our outpatient clinic were included in the study. Thirty of these children had IDA (study group) and the rest were healthy (control group). Thirty patients, meeting the IDA criteria, received oral ferrous sulfate of 4 mg/kg/d. As soon as the hemoglobin value reached >11 g/dL, half dose of oral ferrous sulfate therapy was continued for another month. Serum lipocalin levels before and after iron therapies were compared. Hematologic parameters and serum lipocalin levels were also compared between the 2 groups. Mean values of serum lipocalin were 31.01±14.46 and 74.77 ng/dL in patients with IDA at admission and at third month of therapy, respectively (P<0.0001). The same figure was 57.35±39.51 ng/dL in the control group. Before treatment, mean values of lipocalin levels in patients with IDA was significantly lower than the control group (P=0.001); however, such a difference was not detected after 3 months of therapy (P=0.102). We suggest that decreased serum lipocalin levels in our patients during iron insufficiency were caused by iron deficiency rather than anemia.

E0476 Observation the change of neutrophil gelatinase-associated lipocalin levels in patients undergoing coronary angiography and percutaneous coronary intervention

ObjectiveTo observe the level of neutrophil gelatinase-associated lipocalin (NGAL) in patients undergoing coronary angiography (CAG) and /or percutaneous coronary intervention (PCI) procedure before and after operation and to explore NGAL...

Neutrophil Gelatinase-Associated Lipocalin Levels in Patients With Crohn Disease Undergoing Treatment With Infliximab

Increased levels of neutrophil gelatinase-associated lipocalin (NGAL), a small 25-kd stress protein released by several injured cells, have been reported in different pathological conditions such as kidney and chronic inflammatory...

Neutrophil Gelatinase-Associated Lipocalin Levels in Patients with Thalassemia Intermedia: Lack of Association with Erythropoiesis, Iron Metabolism, Renal Dysfunction and Inflammation.

Neutrophil Gelatinase-Associated Lipocalin (NGAL, 24p3, SIP24, lipocalin-2 or siderocalin) is a novel iron-carrier protein exerting pleiotropic properties. The physiological role of NGAL is not fully elucidated though a few pivotal functions, such as regulation of apoptosis of leukocytes have been described recently. It has also been demonstrated that NGAL is abundantly expressed in erythroid progenitor cells inducing apoptosis and inhibiting their differentiation. NGAL is reduced in the erythroid cells of mice with acute anemia and injection of recombinant lipocalin-2 delayed the recovery of red blood cells suggesting a negative effect of NGAL in accelerating erythropoiesis. The recently reported functions of NGAL on erythroid progenitor cells and its relation to iron transport prompted us to study the pattern of NGAL levels in Thalassemia Intermedia (TI), which is characterized by erythroid progenitor cells hyperactivity and irregularities in iron metabolism (especially iron transport). To this end we measured NGAL levels in 30 patients with TI and in 20 apparently healthy controls matched for age. We also evaluated other parameters that could be possibly related to NGAL's functions as: soluble transferrin receptor (sTfR) for eythroid marrow activity; NTBI concentration for non-transferrin-bound mediate iron delivery pathway; creatinine, cystatin C and β2-microglobulin for renal dysfunction and CRP and IL-6 for low grade inflammation. The main results of the showed that: a) NGAL levels were significantly higher in patients with TI compared to controls (139.1±86.1 vs 51.2±11.8 μg/L, p<0.0001), while 4 patients presented with NGAL levels within normal range, b) in patients with TI no correlation was found between NGAL and the erythropoiesis' parameters Hb, Hb F and sTfR, (p>0.66, p>0.67 and p>0.81 respectively), the parameters of iron metabolism, ferritin and NTBI (p>0.90 and p>0.95 respectively) the markers of renal dysfunction and/or those of low-grade inflammation (p>0.50). The increased NGAL levels observed in TI patients in this study are in agreement with the elevated expression of NGAL observed in experimental models of thalassemia. We postulate that the induction of NGAL in these patients may represent either a response facilitating the survival of the less damaged thalassemic erythroid precursors, or a consequence due to the abnormal iron regulation in patients with TI.